202 Chapter 6 Table 3 – Univariable and multivariable analysis of factors potentially contributing to significant weight loss of >5% during CRT/BRT and to TF dependency significant weight loss of >5% during CRT/BRT Univariable analysis OR CI-95% p value lower upper Age 1.018 0.960 1.078 0.556 Sex (male vs. female) 1.265 0.476 3.363 0.637 Smoking 0.848 0.210 3.434 0.818 Alcohol 1.968 0.781 4.956 0.151 BMI 1.113 1.003 1.236 0.044 Weight loss prior to CRT/BRT 0.941 0.823 1.075 0.370 Dysphagia at start RT (CTCAE grade 2 vs. 0 or 1) 0.521 0.185 1.468 0.217 WHO PS (1 or 2 vs. 0) 0.597 0.221 1.611 0.309 CCI (≥4 vs. <4) 0.738 0.205 2.659 0.642 T3 or T4 vs. T0, T1 or T2 0.599 0.239 1.498 0.273 N2 or N3 vs. N0 or N1 1.821 0.578 5.739 0.306 p16+ vs. p16- 1.579 0.631 3.948 0.329 Edentulous vs. dentate 0.536 0.197 1.462 0.223 Decrease in Eichner Index (ABC) due to tooth extractions prior to CRT/BRT (binary) 1.179 0.291 4.771 0.818 Tooth extractions (yes vs. no) 2.928 1.094 7.834 0.032 Tooth extractions and additional interventions (yes vs. no) 2.435 0.877 6.756 0.087 Number of removed teeth 1.047 0.961 1.140 0.291 Loss of OU due to tooth extractions prior to CRT/BRT 0.867 0.687 1.095 0.232 Cetuximab vs. cisplatin (ref) 1.024 0.375 2.795 0.963 RT dose to contralateral parotid gland 0.975 0.925 1.028 0.347 RT dose to contralateral submandibular gland 1.013 0.973 1.056 0.523 RT dose to superior PCM 1.000 0.954 1.048 0.995 RT dose to median PCM 1.006 0.941 1.075 0.868 RT dose to inferior PCM 1.002 0.956 1.050 0.938 RT dose to oral cavity 0.992 0.950 1.037 0.737 RT dose to cricopharyngeus muscle 0.974 0.911 1.040 0.428 RT dose to cervical esophagus 0.952 0.904 1.002 0.060 TF use 0733 0.292 1.841 0.508 Abbreviations: BMI, body mass index; CCI, Charlson comorbidity index; CRT/BRT, chemoradiotherapy or bioradiotherapy; WHO PS, World Health Organization performance status; OU, occlusal units; PCM, pharyngeal constrictor muscles; RT, radiotherapy; TF, tube feeding;
RkJQdWJsaXNoZXIy MTk4NDMw